How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) issued its quarterly earnings data on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.27. The biopharmaceutical company earned $137.10 million during the quarter, compared to analyst estimates of $97.66 million. GW Pharmaceuticals had a negative trailing twelve-month return on equity of 7.46% and a negative net margin of 11.05%. The business's quarterly revenue was up 50.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) earnings per share.

What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?

14 employees have rated GW Pharmaceuticals Chief Executive Officer Justin Gover on Glassdoor.com . Justin Gover has an approval rating of 80% among the company's employees.

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include NVIDIA (NVDA) , Alibaba Group (BABA) , Micron Technology (MU) , Tesla (TSLA) , Intel (INTC) , Netflix (NFLX) , Gilead Sciences (GILD) , Advanced Micro Devices (AMD) .

NASDAQ:GWPH

GW Pharmaceuticals (GWPH) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free GWPH Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $218.96
▼
$218.96
50-Day Range: $216.90
▼
$219.28
52-Week Range: $87.07
▼
$219.57

Volume: N/A
Average Volume: 899,771 shs
Market Capitalization: $6.86 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get GW Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About GW Pharmaceuticals Stock (NASDAQ:GWPH)

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

GWPH Stock News Headlines

October 14, 2023 | powermag.com

Melaka: Malaysia’s 2.2-GW Cutting-Edge Combined Cycle Gas Power Plant

September 28, 2023 | uk.investing.com

GWPRF Historical Data

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

August 17, 2023 | usnews.com

George Washington University

March 9, 2023 | powermag.com

China Approves 106 GW of New Coal-Fired Capacity

February 19, 2023 | thestreet.com

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

September 25, 2022 | investing.com

GW Pharmaceuticals PLC (GWPRF)

August 22, 2022 | benzinga.com

Medical Marijuana Market Size Worth $40 Billion by 2028 at 19.2% CAGR, COVID-19 Impact and Global Analysis by The Insight Partners

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

June 15, 2022 | thestreet.com

Why Pot Stock GW Pharmaceuticals Could Go Even Higher in 2016

March 3, 2022 | msn.com

Court Dismisses Canopy's Cannabis Patent Infringement Lawsuit Against Jazz's GW Pharma

February 15, 2022 | marketwatch.com

Medical Marijuana Market Forecast With Trends, Challenges, Growth Drivers, And Top Key Players

January 25, 2022 | thestreet.com

These 3 Marijuana-Related Stocks Are Poised for Strong Growth

January 21, 2022 | finance.yahoo.com

GWPH Jan 2023 195.000 put

December 15, 2021 | msn.com

Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment

November 1, 2021 | benzinga.com

Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer

October 26, 2021 | finance.yahoo.com

Today's Research Reports on Trending Tickers: Arena Pharmaceuticals Inc. and GW Pharmaceuticals

October 26, 2021 | finance.yahoo.com

GW Pharmaceuticals (GWPH): What Awaits in Q1 Earnings?

August 4, 2021 | law360.com

2 Firms Seek To Lead GW Pharma Suit Over $7.2B Deal

August 4, 2021 | msn.com

Jazz Pharmaceuticals Q2 Revenue Jumps 34% To $751.8M With $109.5M Epidiolex Net Sales, Reaffirms Its 2021 Guidance Of $3.02B

See More Headlines

Receive GWPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2020
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:GWPH
CUSIP: N/A
CIK: 1351288
Web: www.gwpharm.com
Phone: 44-12-2326-6800
Fax: N/A
Employees: 1,161
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,020,000.00
Net Margins: -11.05%
Pretax Margin: N/A
Return on Equity: -7.46%
Return on Assets: -6.13%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 5.13
Quick Ratio: 4.31

Sales & Book Value

Annual Sales: $311.33 million
Price / Sales: 22.05
Cash Flow: $0.01 per share
Price / Cash Flow: 18,588.22
Book Value: $23.48 per share
Price / Book: 9.33

Miscellaneous

Outstanding Shares: 31,349,000
Free Float: N/A
Market Cap: $6.86 billion
Optionable: Optionable
Beta: 2.15

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Justin D. Gover (Age 50)
CEO & Exec. Director
Comp: $1.19M
Mr. Scott M. Giacobello (Age 51)
Chief Financial Officer
Comp: $743.33k
Mr. Douglas B. Snyder (Age 57)
Chief Legal Officer & Sec.
Comp: $787.02k
Dr. Volker Knappertz M.D. (Age 56)
D.Sc., Chief Medical Officer
Comp: $830.47k
Mr. Christopher John Tovey (Age 56)
Chief Operating Officer
Kristen Cardillo
VP of Corp. Communication
Ms. Tina St. Leger
Chief HR Officer
Prof. Ben Whalley
Head of Discovery Research
Mr. Darren S. Cline (Age 57)
U.S. Chief Commercial Officer

Key Competitors

View All Competitors

GWPH Stock Analysis - Frequently Asked Questions

How were GW Pharmaceuticals' earnings last quarter?: GW Pharmaceuticals plc (NASDAQ:GWPH) issued its quarterly earnings data on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.27. The biopharmaceutical company earned $137.10 million during the quarter, compared to analyst estimates of $97.66 million. GW Pharmaceuticals had a negative trailing twelve-month return on equity of 7.46% and a negative net margin of 11.05%. The business's quarterly revenue was up 50.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.04) earnings per share.
What is Justin Gover's approval rating as GW Pharmaceuticals' CEO?: 14 employees have rated GW Pharmaceuticals Chief Executive Officer Justin Gover on Glassdoor.com. Justin Gover has an approval rating of 80% among the company's employees.
What other stocks do shareholders of GW Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Intel (INTC), Netflix (NFLX), Gilead Sciences (GILD), Advanced Micro Devices (AMD).

This page (NASDAQ:GWPH) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

GW Pharmaceuticals (GWPH) Stock Price, News & Analysis

About GW Pharmaceuticals Stock (NASDAQ:GWPH)

GWPH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

GWPH Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info